Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | GPR34 | Q9UPC5 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | MMP14 | P50281 | 1/20 | 0.41 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13344478 | 1.00 | KMT2A (0.52) | KMT2AGPR34MEN1PTPN1POLB | |
| SCHEMBL3498083 | 0.93 | KMT2A (0.44) | KMT2AGPR34MEN1POLBMAOA | |
| SCHEMBL13344477 | 0.90 | GPR34 (0.63) | KMT2AGPR34MEN1PTPN1MAOA | |
| SCHEMBL3498196 | 0.90 | GPR34 (0.63) | KMT2AGPR34MEN1PTPN1MAOA | |
| SCHEMBL3499991 | 0.90 | GPR34 (0.63) | KMT2AGPR34MEN1PTPN1MAOA | |
| SCHEMBL3500056 | 0.88 | GPR34 (0.54) | KMT2AGPR34MEN1PTPN1POLB | |
| SCHEMBL3500054 | 0.88 | GPR34 (0.54) | KMT2AGPR34MEN1PTPN1POLB | |
| SCHEMBL13344479 | 0.87 | KMT2A (0.53) | KMT2AGPR34MEN1PTPN1POLB | |
| SCHEMBL3498344 | 0.87 | KMT2A (0.53) | KMT2AGPR34MEN1PTPN1POLB | |
| SCHEMBL3499082 | 0.83 | GPR34 (0.54) | KMT2AGPR34MEN1PTPN1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | KMT2A 2910/4885GPR34 1/4885MEN1 3918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.